Study on Therapy of Non-invasive Prolactinoma

Prospective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasive Prolactinoma

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03353025

Acronym

TNAPA

Enrollment

394

Registered

2017-11-24

Start date

2016-01-01

Completion date

2025-12-31

Last updated

2017-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prolactinoma

Keywords

non-invasive prolactinoma

Brief summary

the study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.

Detailed description

Non-invasive prolactinomas were treated by transsphenoidal surgery or Dopamine agonist until now. However，this two type therapies were controversial. The study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.

Interventions

PROCEDUREtranssphenoidal surgery treatment

transsphenoidal surgery treatment

DRUGdopamine agonist treatment

Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

non-invasive prolactionma

Exclusion criteria

invasive prolactioma

Design outcomes

Primary

Measure	Time frame	Description
Endocrine remission rate	five-year	After intervention, blood prolactin normalization rate

Countries

China

Contacts

Primary ContactZongming Wang, Dr.

wzmyan@foxmail.com8613570903721

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026